New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer

Archives of Gynecology and Obstetrics

Volumn 283, Issue 5, 2011, Pages 1087-1096

  Brüning, Ansgar ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Canfosfamide; DNA antagonists; Microtubules; Organoplatinum; Ovarian cancer; Taxanes; Trabectedin

Indexed keywords

5 AMINO 6,8 DIFLUORO 2 (3 FLUOROPHENYL) 7 METHYL 4H 1 BENZOPYRAN 4 ONE; AFP 464; AMINOFLAVONE; ANTINEOPLASTIC AGENT; CANFOSFAMIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERIBULIN; ETOPOSIDE; FLAVONE DERIVATIVE; GEMCITABINE; IXABEPILONE; NSC 707389; NSC 710464; ON 01910; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; VINCA ALKALOID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME SEGREGATION; DIARRHEA; DNA ADDUCT; DNA DAMAGE; DRUG CHOICE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE REPLICATION; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MITOSIS SPINDLE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL DIVISION; DNA; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; MICROTUBULES; OVARIAN NEOPLASMS;

EID: 79956068932     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1757-x     Document Type: Review

References (103)

1. International Agency for Research on Cancer I (2008) Descriptive Epidemiology Group of IARC (2008) GLOBOCAN 2002 database
2. National Cancer Institute (2006) SEER Surveillance, Epidemiology and End Results: SEER Cancer Statistics Review, 1975-2003. http://seer.cancer.gov/csr/ 1975-2003/3
3. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135-166 (Pubitemid 39658498)
4. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9:167-181. doi:10.1038/nrc2583
5. Martin LP, Schilder RJ (2009) Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 36:112-125. doi:10.1053/j.seminoncol.2008.12.003
6. Guth U, Huang DJ, Schotzau A, Wight E (2010) Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients? Arch Gynecol Obstet 281:339-344. doi:10.1007/s00404-009- 1159-0
7. Tixier H, Fraisse J, Chauffert B, Mayer F, Causeret S, Loustalot C, Deville C, Bonnetain F, Sagot P, Douvier S, Cuisenier J (2010) Evaluation of pelvic posterior exenteration in the management of advanced-stage ovarian cancer. Arch Gynecol Obstet 281:505-510. doi:10.1007/s00404-009-1175-0
8. Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ (1993) Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11:434-439 (Pubitemid 23071038)
9. Abaid LN, Goldstein BH, Lopez KL, Micha JP, Brown JV, 3rd, Rettenmaier MA, Markman M (2010) The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy. Arch Gynecol Obstet. doi: 10.1007/s00404-010-1571-5
10. Bilici A, Salepci T, Dane F, Gumus M, Ustaalioglu BB, Seker M, Salman T, Turan C, Unal O, Yaylaci M (2009) Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience. Arch Gynecol Obstet. doi: 10.1007/s00404-009-1330-7
11. Guth U, Kann SR, Huang DJ, Schotzau A, Holzgreve W, Wight E (2009) Systemic therapy developments and their effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease. Arch Gynecol Obstet 280:719-724. doi: 10.1007/s00404-009-0995-2
12. Lenhard SM, Bufe A, Kumper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K, Burges A (2009) Relapse and survival in early-stage ovarian cancer. Arch Gynecol Obstet 280:71-77. doi:10.1007/s00404-008-0877-z
13. Matsuo K, Eno ML, Im DD, Rosenshein NB (2010) Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch Gynecol Obstet 281:325-328. doi:10.1007/s00404-009- 1121-1
14. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329
15. Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Yeap BY et al (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78:1479-1487 (Pubitemid 28517545)
16. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200. doi:10.1200/JCO.2003.02.153
17. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717
18. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G et al (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726
19. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524 (Pubitemid 24330215)
20. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79
21. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol. doi:10.1200/JCO.2008.19.1684
22. Muggia F (2009) Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112:275-281. doi:10.1016/j.ygyno.2008.09.034
23. Borst P, Rottenberg S, Jonkers J (2008) How do real tumors become resistant to cisplatin? Cell Cycle 7:1353-1359. doi: 5930[pii]
24. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650-653 (Pubitemid 19111764)
25. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393
26. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
27. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232-1237 (Pubitemid 34177429)
28. Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E (1999) Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 72:60-64. doi:10.1006/gyno.1998.5237 (Pubitemid 29045448)
29. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193
30. Sehouli J, Oskay-Ozcelik G (2009) Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin 25:639-651. doi:10.1185/03007990802707139
31. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322 (Pubitemid 32642183)
32. Rose PG, Blessing JA, Mayer AR, Homesley HD (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405-410 (Pubitemid 28135580)
33. Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12:1705-1709 (Pubitemid 34105660)
34. van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, Verweij J (2002) Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86:19-25. doi:10.1038/sj.bjc.6600002 (Pubitemid 34146335)
35. Sedletska Y, Giraud-Panis MJ, Malinge JM (2005) Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 5:251-265 (Pubitemid 40655276)
36. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23. doi:10.1016/j.ctrv.2006.09.006 (Pubitemid 46137553)
37. Chaney SG, Campbell SL, Bassett E, Wu Y (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53:3-11. doi:10.1016/j.critrevonc.2004.08.008 (Pubitemid 39656106)
38. Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K (2006) Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol Ther 5:943-949
39. Negoro K, Yamano Y, Nakashima D, Saito K, Nakatani K, Shiiba M, Bukawa H, Yokoe H, Uzawa K, Wada T, Tanzawa H, Fujita S (2009) Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line. Oncol Rep 21:443-449
40. Stordal B, Pavlakis N, Davey R (2007) A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 33:688-703. doi:10.1016/j.ctrv.2007.07.013 (Pubitemid 350089290)
41. Fu S, Kavanagh JJ, Hu W, Bast RC Jr (2006) Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 16:1717-1732. doi:10.1111/j.1525-1438.2006.00654.x (Pubitemid 44470028)
42. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaine MA, Itzhaki M, Marty M, Extra JM (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10:1125-1128 (Pubitemid 29482472)
43. Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E (2006) A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 17:429-436. doi:10.1093/annonc/mdj097 (Pubitemid 43329579)
44. Ferrandina G, Ludovisi M, De Vincenzo R, Salutari V, Lorusso D, Colangelo M, Prantera T, Valerio MR, Scambia G (2007) Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 18:1348-1353. doi:10.1093/annonc/mdm136 (Pubitemid 47305008)
45. Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, Grijuela B, Fontanelli R, Solima E, Spatti G, Scibilia G, Kusamura S (2004) Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67:376-381. doi:10.1159/000082921
46. Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, De Souza P, Links M, Kalimi G, Davies T, Stuart-Harris R (2007) Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 17:359-366. doi:10.1111/j.1525-1438.2007.00763.x (Pubitemid 46426756)
47. Germano D, Rosati G, Manzione L (2007) Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. J Chemother 19:577-581 (Pubitemid 350177969)
48. Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Levy E, Hardy-Bessard AC, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H, Agostini C, Provencal J, Ferrero JM, Fric D, Dohollou N, Paraiso D, Salvat J, Pujade-Lauraine E (2009) Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 100:601-607. doi:10.1038/sj.bjc.6604878
49. Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G, Ferrazzi E, Perin A, Donach M, Zoli W (2006) Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol 100:318-323. doi: 10.1016/j.ygyno.2005.08.020 (Pubitemid 43075263)
50. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Carta G, Necozione S, Mantovani G, Rea S (2007) A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol 106:164-169. doi:10.1016/j.ygyno.2007.03.015 (Pubitemid 46898588)
51. Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA (2004) Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 95:165-172. doi:10.1016/j.ygyno.2004.06.029 (Pubitemid 39286293)
52. Sundar S, Symonds RP, Decatris MP, Kumar DM, Osman A, Vasanthan S, O'Byrne KJ (2004) Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 94:502-508. doi:10.1016/j.ygyno.2004.04. 020 (Pubitemid 39024560)
53. Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Naniwa J, Uegaki K, Nonaka M, Terakawa N (2009) Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 100:546-551. doi:10.1111/j.1349-7006.2008.01065.x
54. Elkas JC, Winter WE 3rd, Chernofsky MR, Sunde J, Bidus MA, Bernstein S, Rose GS (2007) A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 104:422-427. doi:10.1016/j.ygyno.2006.08.011 (Pubitemid 46135647)
55. Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F (2008) Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol 108:500-504. doi:10.1016/j.ygyno.2007.11.017
56. Verschraegen CF, Glover K (2001) ET-743 (PharmaMar/NCI/Ortho Biotech). Curr Opin Investig Drugs 2:1631-1638
57. Aune GJ, Furuta T, Pommier Y (2002) Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 13:545-555 (Pubitemid 34816449)
58. D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT (2003) The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 39:1920-1926 (Pubitemid 37311190)
59. Carter NJ, Keam SJ (2007) Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67:2257-2276 (Pubitemid 47557097)
60. Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT (2008) Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 9:1609-1618. doi:10.1517/14656566.9.9.1609 (Pubitemid 352005920)
61. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309. doi: 10.1021/bi960306b (Pubitemid 26349423)
62. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y (2001) Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 7:185-191 (Pubitemid 32110222)
63. Guirouilh-Barbat J, Redon C, Pommier Y (2008) Transcriptioncoupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 19:3969-3981. doi:10.1091/mbc.E08-02- 0215
64. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977-1983 (Pubitemid 28369184)
65. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT (1999) High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10:1233-1240 (Pubitemid 29533575)
66. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD (1998) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981-987
67. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'IncalciM, Dall'o E, Colombo N (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-1874. doi:10.1200/JCO.2005.09. 032
68. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME (2007) A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97:1618-1624. doi:10.1038/sj.bjc.6604088 (Pubitemid 350249358)
69. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 20:1794-1802. doi:10.1093/annonc/mdp198
70. Del Campo JM, Munoz-Couselo E, Diaz de Corcuera I, Oaknin A (2010) Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer. Expert Rev Anticancer Ther 10:795-805. doi:10.1586/era.10.59
71. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM (2010) Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107-3114. doi:10.1200/JCO.2009.25.4037
72. Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, Lebedinsky C, Parekh T, Santabarbara P, Park YC, Nieto A, Poveda A (2010) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol doi:10.1093/annonc/mdq353
73. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gomez J, Park YC, Alfaro V, Monk BJ (2010) Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol doi: 10.1093/annonc/mdq352
74. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, Pommier Y (2005) DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65:5337-5343. doi: 10.1158/0008-5472.CAN- 05-0003 (Pubitemid 40827346)
75. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM (2002) Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143-153 (Pubitemid 34680526)
76. McLean L, Soto U, Agama K, Francis J, Jimenez R, Pommier Y, Sowers L, Brantley E (2008) Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int J Cancer 122:1665-1674. doi: 10.1002/ijc.23244 (Pubitemid 351294978)
77. Pobst LJ, Ames MM (2006) CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother Pharmacol 57:569-576. doi:10.1007/s00280-005-0075-7 (Pubitemid 43237840)
78. Kosmider B, Wojcik I, Osiecka R, Bartkowiak J, Zyner E, Ochocki J, Liberski P (2005) Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Invest New Drugs 23:287-297. doi:10.1007/s10637-005-1437-z (Pubitemid 40980351)
79. Meng LH, Meng Z, Miao ZH, Veenstra TD, Pommier Y (2008) Cytokeratin-RNA cross-linking mediated by the antitumor aminoflavone, 5-amino-2, 3-fluorophenyl-6, 8-difluoro-7-methyl-4H-1-benzopyran-4-one. J Pharmacol Exp Ther 325:674-680. doi:10.1124/jpet.108.137802 (Pubitemid 351574796)
80. Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM (1998) Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 58:2568-2575 (Pubitemid 28275427)
81. Tew KD (2005) TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 14:1047-1054. doi:10.1517/13543784.14.8.1047
82. Townsend DM, Shen H, Staros AL, Gate L, Tew KD (2002) Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 1:1089-1095
83. Kavanagh JJ, Gershenson DM, Choi H, Lewis L, Patel K, Brown GL, Garcia A, Spriggs DR (2005) Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 15:593-600. doi:10.1111/j.1525-1438.2005.00114.x (Pubitemid 41022895)
84. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S (2009) Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or - resistant ovarian cancer. Eur J Cancer 45:2324-2332. doi: S0959-8049(09)00346- 3[pii]10.1016/j.ejca.2009.05.016
85. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC Jr (2010) Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol 3:9. doi: 10.1186/1756-8722-3-9
86. Kuppens IE (2006) Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 1:57-70
87. Fojo T, Menefee M (2007) Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 18(Suppl 5):v3-v8. doi:10.1093/annonc/mdm172
88. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physicochemical and biological properties. J Antibiot (Tokyo) 49:560-563 (Pubitemid 26235665)
89. Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167-7172. doi: 10.1158/1078-0432.CCR-08-0169
90. Steinberg M (2008) Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Clin Ther 30:1590-1617. doi:10.1016/j.clinthera.2008.09.015
91. Yardley DA (2008) Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 8:487-492. doi:10.3816/CBC.2008.n.058
92. Larkin JM, Kaye SB (2007) Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 18 Suppl 5:v28-v34. doi:10.1093/annonc/mdm176
93. Gupta D, Mani S (2009) The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies. Expert Opin Drug Saf 8:81-88. doi: 10.1517/14740330802655538
94. De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE (2010) Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 28:149-153. doi:10.1200/JCO.2009.24.1455
95. Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C (2007) A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs 25:335-341. doi:10.1007/s10637-007-9035-x (Pubitemid 46944846)
96. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, Spanik S, Wagnerova M, Hirte HW, Kaye S, Johri AR, Oza AM (2009) Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 27:3097-3103. doi:10.1200/JCO.2008.20.4826
97. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP (2006) Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 16:5093-5096. doi:10.1016/j.bmcl.2006.07. 030
98. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P (2009) Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 49:1467-1476. doi:10.1177/0091270009339740
99. Newman S (2007) Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs 8:1057-1066
100. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013-1021
101. Barr FA, Sillje HH, Nigg EA (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5:429-440. doi:10.1038/nrm1401 (Pubitemid 38745493)
102. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP (2005) ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7:275-286. doi:10.1016/j.ccr.2005.02.009 (Pubitemid 40568686)
103. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC (2008) Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 26:5504-5510. doi:10.1200/JCO.2008.17.9788